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Calcific aortic valve disease is the most common valvular disease and confers significant
morbidity and mortality. There are currently no medical therapies that successfully halt or
reverse the disease progression, making surgical replacement the only treatment currently
available. The majority of patients will receive a bioprosthetic valve, which themselves are
prone to degeneration and may also need replaced, adding to the already substantial healthcare
burden of aortic stenosis. Echocardiography and computed tomography can identify late-stage
manifestations of the disease process affecting native and bioprosthetic aortic valves but cannot
detect or quantify early molecular changes. 18F-fluoride positron emission tomography, on the
other hand, can non-invasively and sensitively assess disease activity in the valves. The current
review outlines the pivotal role this novel molecular imaging technique has played in improving
our understanding of native and bioprosthetic aortic valve disease, as well as providing insights
into its feasibility as an important future research and clinical tool.
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Abbreviations
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NaF
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HALT Hypoattenuated leaflet thickening
PET Positron emission tomography
CT Computed tomography
TAVI Transcatheter aortic valve implantation
TTE Transthoracic echocardiography
TEE Transesophageal echocardiography
INTRODUCTION
Aortic stenosis affects 1-2% of the general popula-
tion [65 years old, conferring with it increased
mortality.1,2 Current international guidance recommends
that the aortic valve should be replacement in those with
severe, symptomatic aortic stenosis; a procedure which
carries morbidity and significant cost.1,3–5 Replacement
with a bioprosthetic valve is recommended in those over
65-70 years old, with mechanical valves preferred in the
minority of younger patients.6 Bioprosthetic valves are
beneficial in that they do not require the life-long
anticoagulation that comes with mechanical valve
implantation; however, they are prone to degradation
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over a relatively short time-span of*15 years.6 Medical
therapies that prevent progression of native or biopros-
thetic aortic valve disease would represent a significant
step in the management of these patient groups, but have
so far remained elusive. To develop successful targeted
medical therapy, identification of the mechanisms driv-
ing the disease process is crucial. Conventional imaging
with computed tomography (CT) or transthoracic
echocardiography (TTE) can identify the structural and
haemodynamic manifestations of valvular disease; how-
ever, they cannot provide information about the
molecular processes underpinning valve disease. Molec-
ular imaging, on the other hand, can identify and
quantify disease activity non-invasively and has an
emerging role in evaluating the efficacy of medical
therapies in randomized controlled trials as well a
possible clinical utility in the early detection of aggres-
sive disease.7 The current review outlines the pivotal
role molecular imaging has played in our understanding
of disease mechanisms, as well as providing insights
into its feasibility as an important future research and
clinical tool in the setting of native and bioprosthetic
aortic valve disease.
DISEASE OF THE NATIVE AORTIC VALVE
The aortic valve is located at the junction between
the left ventricle and aorta and functions to prevent
backflow of blood into the left ventricle during diastole
while allowing unimpaired systolic ejection. Anatomi-
cally, the aortic valve consists of three leaflets that are
anchored to a crown-like anulus. During diastole, the
high aortic pressures force the leaflets to coapt, closing
the valve and forming three blood-filled sinuses; two of
which contain coronary arteries and facilitate blood
flow. The aortic leaflets are highly specialized structures
that must be compliant enough to open without resis-
tance to blood flow, while being strong enough to
withstand the repeated mechanical stresses applied
throughout the cardiac cycle. In aortic stenosis, diseased
valve leaflets become stiff and lose compliance, increas-
ing the intraventricular pressure required to generate the
same flow across the valve. The current model of native
aortic valve pathology is thought to involve an initiation
phase, where initial valvular injury leads to inflamma-
tion, immune activation and initial calcium deposition,
followed by a propagation phase, involving a damaging
cycle of increasing calcification activity.8 Increasing
haemodynamic resistance across the valve can be
identified with transthoracic echocardiography (TTE),
while end-stage structural valve disease can be seen as
valvular calcification identified on computed tomogra-
phy (CT). Both TTE and CT calcium scoring have been
integrated into international guidelines to determine
when to perform aortic valve replacement.3,4 However,
by the time haemodynamic changes or overt calcific
disease are seen on TTE or CT, these disease processes
are already well under way. The development of a
successful medical therapy will depend on identifying
and understanding the details of the active disease
processes leading to these structural and haemodynamic
changes.
CALCIFICATION AS THE DRIVER OF DISEASE
IN NATIVE AORTIC VALVE STENOSIS
Due to a strong overlap between risk factors for
developing atherosclerosis and aortic stenosis, the lipid-
lowering effect of statins was initially investigated as a
means of slowing aortic stenosis progression. Frustrat-
ingly, multiple randomized controlled trials did not
demonstrate a reduction in aortic valve velocity or
calcium score progression over medium-term follow-
up.7,9 While disappointing, the results also questioned
the understood inflammatory mechanisms driving the
process of aortic stenosis.
To explore the relative contributions of inflamma-
tory and calcific processes to aortic stenosis in vivo,
researchers performed hybrid positron emission tomog-
raphy combined with computed tomography (PET/CT),
comparing 18F-fluorodeoxygloucose, (18F-FGD), a non-
specific marker of inflammation, and 18F-sodium fluo-
ride (18F-NaF), which preferentially binds to developing
microcalcification, in a cohort of patients with varying
degrees of aortic stenosis. The results demonstrated that
calcification activity dominated over inflammation in
aortic stenosis, particularly in the latter stages of
moderate or severe stenosis (Fig. 1).10 The reverse
situation was observed in concomitant regions of
atheroma, with inflammation predominating: an obser-
vation that perhaps explains the differential effects of
statins in these two conditions.11 Importantly, the
anatomical pattern of 18F-NaF uptake at baseline was
different to the presence of baseline calcium on CT,
confirming that these two modalities provide different
information. However, this baseline 18F-NaF PET
activity did predict where new regions of calcium on
CT would develop after 1-2 years of follow-up (Fig. 2).
Similar observations have been made in different car-
diovascular conditions (e.g., mitral annular calcification
and coronary atherosclerosis)12,13 supporting 18F-NaF
PET as a marker of newly developing calcification
beyond the resolution of CT and as a marker of disease
activity in aortic stenosis. Overall in the population of
121 patients, baseline 18F-NaF closely predicted pro-
gression of aortic valve calcium score after 2 years
(R = .80, P\ .001) as well as clinical events (aortic
valve replacement or death).14,15
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ACCURATELY MEASURING AORTIC VALVE 18F-
SODIUM FLUORIDE UPTAKE
While the early studies described above demon-
strate that 18F-NaF is a potentially useful biomarker,
recent advances in imaging protocols have improved
image quality and reproducibility of measurements,
thereby enhancing this technique. A detailed description
of standardized analysis techniques have been previ-
ously outlined.16,17 Utilization of contrast-enhanced
computed tomography was an important advance,
allowing accurate co-registration of the PET and CT
scans by lining up the relatively high 18F-NaF activity
in the blood pool compared to the myocardium with the
left ventricular cavity visualized on contrast-enhanced
CT in three orthogonal planes (Fig. 3). Moreover, this
provides increased anatomical detail of the valve,
allowing differentiating of 18F-NaF uptake in the valve
from adjacent structures such as the aorta and coronary
arteries. Motion correction techniques have proved
similarly important. Motion of the valve throughout
the cardiac cycle produces a wider distribution of PET
Figure 1. Uptake of 18F-fluorodeoxyglucose (18F-FDG) and
18F-sodium fluoride (18F-NaF) according to the severity of
aortic stenosis. Box plots show the median and interquartile
ranges of the tissue-to-background ratios (TBR) for 18F-NaF
(white boxes) and 18F-FDG (gray boxes) with whiskers to 1.5
interquartile range. Figure reproduced with permission from
Dweck et al.10.
Figure 2. Two patients with progressive calcific aortic valve disease. (Left) Baseline computed
tomography (CT) images. (Middle) Fused positron emission tomography (PET)-CT images
showing increased 18F-fluoride valvular uptake (red/yellow areas). (Right) Repeat CT scans after 14
months with progressive aortic valve calcium score and new macroscopic calcium (white areas) in a
similar distribution to that of baseline PET uptake. 18F-NaF PET-CT, 18F-sodium fluoride; PET,
positron emission tomography; CT, computed tomography; Ca Score, Calcium score in Agatston
units; TBRmax, maximum tissue-to-background ratio.
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signal, therefore, ECG-gating that captured the valve in
diastole (50-75% RR interval) was employed to improve
reproducibility.16,18 However, ECG-gating in this man-
ner excludes 75% of potential data capture, increasing
noise. Researchers have therefore developed a ‘motion
correction’ algorithm that tracks the PET signal through-
out each ECG gate and then collates all data to a single
gate. This corrects for cardiac motion but does not
involve data loss and therefore improves the signal-to-
noise ratio (Fig. 4).19 Further iterations of this approach
now allow additional correction for respiratory motion
as well as bulk motion artifact.20 The final important
advance has been in the approach to quantification. The
‘most diseased segment’ method, which averages the
mean or maximum PET uptake values of the hottest two
slices, precludes reproducibility issues associated with
identifying the top and bottom slices of the valve.
When the above advances are combined, scan–
rescan measurement error falls from[60% to 10%.16,18
With this degree of reproducibility, 18F-NaF becomes a
crucial tool for elucidating novel insights in to the
pathology of aortic stenosis and bioprosthetic valve
degeneration as well as an efficacy endpoint in random-
ized controlled trials of novel therapies.
18F-SODIUM FLUORIDE IN CLINICAL RESEARCH
Using PET/CT 18F-sodium fluoride activity, the
relationship between possible disease instigators and
aortic valve disease can be investigated. Both lipopro-
tein(a) and oxidized phospholipids have been genetically
linked to an increased incidence of aortic stenosis in the
general population; however, whether these lipid mark-
ers are also associated with the propagation phase of
aortic stenosis and faster disease progression remained
uncertain.21-23 In a recent study of patients with calcific
aortic valve disease, high levels of lipoprotein(a) or
oxidized lipoprotein (the top tertile) were shown to be
associated with higher baseline aortic valve 18F-NaF
uptake, with this increased PET activity translating in to
faster progression of the aortic valve CT calcium score,
and more rapid progression of haemodynamic gradients
on echocardiography.24 Raised oxidized phospholipids
and lipoprotein(a) levels are therefore associated with an
increased incidence and rate of progression in aortic
stenosis and are therefore important potential therapeu-
tic targets for patients with increased levels.24 Indeed,
currently two randomized controlled trials are ongoing
which assess the effect of niacin (NCT02109614) or
PCSK9 inhibitors (NCT03051360) on lipoprotein(a)
lowering and aortic stenosis progression; the latter using
18F-NaF uptake as a primary outcome.22
18F-SODIUM FLUORIDE AS A CLINICAL TOOL
IN NATIVE AORTIC VALVE STENOSIS
Given the ability of 18F-NaF to measure disease
activity and predict disease progression and clinical
events in aortic stenosis, is there a role for this technique
in clinical practice?25 The substantial costs and radiation
exposure associated with 18F-NaF PET/CT means that it
would need to provide incremental information to
established echocardiographic and CT approaches.
However, the studies reported to date have suggested
that CT calcium scoring provides similar prognostic and
predictive information to PET.15 In large part, this is due
to the reasonably close association between baseline
18F-NaF PET activity and CT calcium scores. While at
present this argues for wider use of CT and against
routine 18F-NaF PET imaging, it does provide important
pathophysiological insights. In particular, it suggests
Figure 3. Improved localization of positron emission tomog-
raphy (PET) signal within the aortic valve and its leaflets.
Paired non-contrast PET-computed tomography (CT) scans
(left) and contrast-enhanced PET-CT images (right). Images
demonstrate the typical distribution of the tracer uptake within
the valve at sites of increased mechanical stress, that is, at the
leaflet tips (top, blue arrow) and at the commissures (middle,
blue arrows). Contrast enhancement also aids identification of
valvular and peri-valvular uptake, for example in the coronary
arteries (bottom, blue arrow). Scale bars represent standardized
uptake values (SUV). PET, positron emission tomography; CT,
computed tomography.
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that calcium in the valve leaflets encourages further
calcification activity and faster disease progression,
perhaps via the increase in associated mechanical
stresses within the valve. The result is a vicious cycle
of progressive calcification that drives the propagation
phase of aortic stenosis and suggests that calcification
should be the predominant target for future therapies.
Two ongoing randomized controlled trials are investi-
gating this hypothesis, assessing the effect of denosumab
or alendronate (SALTIRE II, NCT02132026) and vita-
min K2 (BASIK 2, NCT02917525) on aortic stenosis
progression (Table 1).26 18F-NaF is being used as an
efficacy endpoint in both trials.
Further prospective studies are now ongoing to
assess whether 18F-NaF PET imaging using the latest
protocols and image analysis approaches can provide the
incremental predictive information that would support a
more extensive clinical role.
BIOPROSTHETIC AORTIC VALVE
DEGENERATION
Bioprosthetic aortic valves are preferred in patients
[65 years old because of reduced thrombogenicity and
no requirement for long term anticoagulation. While
there has been significant improvement in longevity
since the introduction of bioprosthetic valves in the
1960s, the propensity towards structural deterioration
over 10-20 years remains a major limitation to their use
in younger patients.27,28 Typically, bioprosthetic valves
are made of a covered frame with valve leaflets
fashioned from either explanted porcine aortic valve or
bovine pericardium. The pathological pathways under-
pinning bioprosthetic valve degradation are not fully
understood, but are thought to involve microthrombus,
pannus formation and excess mineralization consequent
to plasminogen/fibrinogen, myofibroblast and macro-
phage-driven responses, respectively, quite different
from those affecting the native valve.29-32 Structural
valve degeneration (SVD) is defined as intrinsic leaflet
deterioration associated with eventual haemodynamic
dysfunction, and is categorized into four major stages:
stage 0, no evidence of SVD; stage 1, SVD without
significant haemodynamic changes (no/mild stenosis or
regurgitation); stage 2, SVD with moderate stenosis or
regurgitation; stage 3, SVD with severe stenosis or
regurgitation, with re-intervention considered once
symptoms develop in patients with severe disease.33
Standard assessment involves TTE (or transesophageal
echocardiograph if TTE windows are poor) at baseline,
one month after implantation and then annually to assess
for changes in haemodynamic gradient.4,33,34 TTE/TEE
is ideal for assessing haemodynamic changes and can
identify gross leaflet abnormalities such as fluttering,
thickening, or abnormal opening; however, echocardio-
graphy frequently only identifies end-stage valve
degeneration with patients presenting in extremis and
misses the earlier stage of its development. Computed
tomography has been utilized to identify early and subtle
changes on the valve which may not be seen on TTE/
TEE, particularly thrombus and pannus formation, with
hypoattenuated leaftlet thickening (HALT) seen in 4-7%
of surgical bioprosthetic aortic valves at various periods
after implantation.35,36 However, this imaging technique
is also limited by imaging artifact related to the stent
frame and motion in patients that frequently cannot
receive beta-blockade. Moreover although CT can iden-
tify these changes, the clinical implications are not clear,
Figure 4. Fused 18F-fluoride PET/contrast-enhanced MR angiograms of aortic valve of 60-year old
man with aortic stenosis. Shown are original diastolic gate (A), summed image (B), and motion-
corrected image (C) with focal 18F-fluoride uptake (arrows). This research was originally published
in JNM. Doris et al.19  SNMMI.
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with no difference in hemodynamic gradient or out-
comes at one year in those with and without HALT.37 A
biomarker which could sensitively detect the early
stages of bioprosthetic degeneration and predict eventual
deterioration would, therefore, fill an important area of
clinical need.
As bioprosthetic valve leaflet calcification appears
central to structural deterioration, researchers investi-
gated the relationship between SVD and calcification
ex vivo using explanted surgical bioprosthetic valves and
18F-NaF microPET/CT. Various pathological processes,
including overt nodular calcification, thrombus, pannus
and non-specific leaflet thickening were all visually
highlighted by 18F-NaF, and correlated with pathology
on histological staining (Fig. 5), suggesting calcification
as a common endpoint for a variety of different triggers
to bioprosthetic degeneration.38 In a prospective study,
80 patients recruited 1 month - 20 years after surgical
bioprosthetic aortic valve replacement received baseline
18F-NaF PET/CT and TTE, with follow-up at 2 years.
The same pathological processes were identified in vivo
as seen in the explanted tissue (Fig. 6).38 Seventy one
patients who had no echocardiographic evidence of
valve dysfunction at baseline, 19% were found have
pathological CT change, while a third had evidence of
increased 18F-sodium fluoride uptake. Of the 67 who had
available follow-up data, 10 (15%) developed new valve
dysfunction, with two requiring urgent valve replace-
ment and one death directly related to valve failure.
Crucially, in multivariable linear regression analysis,
baseline 18F-NaF was the only predictor of bioprosthetic
valve dysfunction outperforming age, echocardiographic
findings, CT findings, valve age and gender (Fig. 7). The
patients who developed overt valve failure all had
intense 18F-NaF baseline activity. 18F-NaF PET/CT
therefore holds major promise for the early detection of
bioprosthetic valve degeneration with potentially impor-
tant clinical implications on the intensity of follow-up,
and timing of replacement surgery for patients. Estab-
lishing the clinical role for 18F-NaF PET/CT in these
patient groups will require validation in larger multi-
center prospective studies.
CONCLUSIONS
Aortic stenosis and bioprosthetic aortic valve
degeneration represent major health problems that,
despite considerable research effort, currently lack
effective preventative medical therapies. Calcification
activity, as quantified non-invasively using 18F-NaF
PET/CT, has been identified as the primary driver of
both types of disease. Recent optimization of 18F-NaF
PET has made it a sensitive and reproducible marker of
aortic stenosis disease activity, providing important
pathological insights and an efficacy endpoint in mul-
tiple ongoing randomized controlled trials. However,
perhaps the most promising clinical translation for 18F-
NaF PET lies in bioprosthetic aortic valve degeneration,
where it can provide an early assessment of valve
Table 1. Ongoing clinical trials in aortic stenosis using 18F-NaF as an endpoint
Reference
Trial
number Design Outcome measures
PCSK9 Inhibitors in
the Progression
of Aortic
Stenosis
NCT03051360 140 patients mild-moderate aortic
stenosis: 70 PCSK9 inhibitors vs 70
placebo
Primary: Change in aortic valve
CT calcium score and Change
in aortic valve 18F-NaF PET/CT
SALTIRE II NCT02132026 150 patients with aortic Vmax[2.5 m/s
and at least mild calcification seen on
echo: 50 alendronic acid (70 mg/
week) vs 50 Denosumab injection 6
monthly vs 50 placebo (25 tabs, 25
injection)
Primary: Change in valve calcium
score
Secondary: Change in valve 18F-
NaF PET/CT
BASIK2 NCT02917525 44 patients with bicuspid aortic valve
mild-moderate calcific aortic stenosis:
22 vitamin K2 (360 lg/day for 18
months)
22 placebo (for 18 months)
Primary: Change in 18F-NaF PET/
MR
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Figure 5. (Row A) Macroscopic visual appearances of failed and explanted bioprosthetic valves.
(Row B) CT en face images of the valves. (Row C) PET en face images demonstrating increased
18F-fluoride uptake in all valves. (Row D) Histology staining of sections taken from valve leaflet as
indicated, with von Kossa (top row, calcium appears black), Movat Pentachrome (bottom row,
valves 1 and 4), and hematoxylin and eosin (bottom row, valves 2 and 3) stains. All 4 degenerate
bioprostheses demonstrate increased 18F-fluoride uptake in the valve leaflets. In valve 1, this uptake
corresponds to gross leaflet calcification observed macroscopically and on CT images with
confirmation on histology (extensive black staining). In valve 2, increased 18F-fluoride uptake is
observed in association with fibrotic leaflet thickening and pannus (red arrows) with associated
calcification (black arrows) observed macroscopically and on CT with confirmation on histology. In
valve 3, increased 18F-fluoride uptake is observed at the site of valve leaflet thrombus (red arrow)
observed macroscopically at the base of leaflet 1, with confirmation of thrombus (red arrow) and
colocalized calcification (black arrow) on histology. In valve 4, extensive 18F-fluoride uptake is
observed in the absence of calcification on CT and histology but instead in areas of leaflet
thickening, marked fluid insudation, and disrupted collagen architecture. CT, computed tomogra-
phy; PET, positron emission tomography. Adapted from Timothy et al.38 Under creative commons
licence.
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Figure 6. Baseline CT (left) and 18F-fluoride PET (right) images from patients with bioprosthetic
aortic valves. En face CT images of aortic bioprosthetic valves showing spotty calcification and
large calcification (top left), circumferential pannus (bottom left), and noncalcific leaflet thickening
suggestive of thrombus (top right) (all abnormalities identified by red arrows). Hybrid en face PET-
CT images in the same patients: increased bioprosthetic 18F-fluoride activity (red/yellow areas) is
observed in each patient colocalizing with the CT abnormalities. 18F-fluoride activity was also
commonly observed remote from leaflet changes on CT (bottom right). Scale bars in the center of
each pair of images represent standardized uptake values (SUV). Target-to-background (TBR)
values are annotated on the hybrid PET-CT images in white text. Adapted from Timothy et al.38
Under creative commons licence.
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degeneration not currently offered by other imaging
techniques.
Open Access
This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use,
sharing, adaptation, distribution and reproduction in any
medium or format, as long as you give appropriate credit to
Figure 7. (A) A strong correlation was observed between baseline 18F-fluoride uptake in the
bioprosthetic valves (TBR) and subsequent progression in bioprosthetic valve peak velocity (log
transformation applied; r = 0.72; P\ .001). Orange dots signify patients who developed new
bioprosthetic valve regurgitation during follow-up. (B) 18F-fluoride uptake (dashed orange line
represents threshold for increased 18F-fluoride uptake; TBR 1.3) in patients with different stages of
structural valve degeneration after 2-year follow-up (stage 0: no significant change from post-
implantation [n = 54]; stage 1: morphological abnormalities without significant hemodynamic
changes [n = 9]; stage 2: new moderate stenosis and/or regurgitation [n = 5]; stage 3: new severe
stenosis and/or severe regurgitation [n = 2]) demonstrating incrementally higher uptake values with
increasing severity of structural valve degeneration. (C and D) Forest plots of unstandardized
coefficients (95% confidence intervals) from a multivariable linear regression analysis predicting
change in bioprosthetic valve function (annualized change in peak velocity) during follow-up.
When examining all relevant baseline characteristics, 18F-fluoride uptake was the only independent
predictor of hemodynamic deterioration in valve function when used both as a dichotomous
variable (PET, TBR[ 1.3) (C) and as a continuous variable (TBR) (D). CI, confidence interval.
Adapted from Timothy et al.38 Under creative commons licence.
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the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article
are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material
is not included in the article’s Creative Commons licence and
your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission
directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
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